Gene Therapy, #Yescarta (axicabtagene ciloleucel), Approved for B-Cell Lymphoma

THURSDAY, Oct. 19, 2017 --Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration as the first form of gene therapy for a non-Hodgkin lymphoma (NHL) form of cancer. Diffuse large B-cell lymphoma is the most...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news